Bulletin
Investor Alert

London Markets Open in:

Keros Therapeutics Inc.

NAS: KROS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 30, 2020, 4:01 p.m.

/zigman2/quotes/217766474/composite

$

75.61

Change

0.00 0.00%

Volume

Volume 24,099

Quotes are delayed by 20 min

/zigman2/quotes/217766474/composite

Previous close

$ 76.00

$ 75.61

Change

-0.39 -0.51%

Day low

Day high

$69.68

$79.44

Open

52 week low

52 week high

$19.10

$81.00

Open

Company Description

Keros Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on treatments for rare muscle diseases. The company was founded in 2015 and is headquartered in Lexington, MA.

Valuation

Efficiency

Revenue/Employee

434,783.00

Income Per Employee

-536,348.00

Receivables Turnover

21.69

Total Asset Turnover

0.52

Liquidity

Current Ratio

1.86

Quick Ratio

1.86

Cash Ratio

1.56

Profitability

Operating Margin

-105.63

Pretax Margin

-123.36

Net Margin

-123.36

Return on Assets

-64.31

Return on Total Capital

-93.21

Return on Invested Capital

-111.53

Capital Structure

Total Debt to Total Capital

389.12

Total Debt to Total Assets

238.90

Long-Term Debt to Total Capital

383.53

Officers and Executives

Name Age Officer Since Title
Dr. Jasbir S. Seehra 63 2015 President, Chief Executive Officer & Director
Mr. Keith C. Regnante 49 2020 Chief Financial Officer
Dr. Jennifer Lachey 46 2016 Chief Scientific Officer
Dr. Claudia Ordonez 53 2019 Chief Medical Officer
Mr. Nima M. Farzan 43 2020 Independent Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/17/2020 Pontifax Management Co. Ltd.
6,000   Acquisition at $50 per share. 300,000
11/17/2020 Pontifax Management Co. Ltd.
14,400   Acquisition at $50 per share. 720,000
11/17/2020 Pontifax Management Co. Ltd.
12,966   Acquisition at $50 per share. 648,300
11/17/2020 Pontifax Management Co. Ltd.
26,634   Acquisition at $50 per share. 1,331,700
11/17/2020 Pontifax Management Co. Ltd.
6,000   Acquisition at $50 per share. 300,000
11/17/2020 Pontifax Management Co. Ltd.
14,400   Acquisition at $50 per share. 720,000
11/17/2020 Pontifax Management Co. Ltd.
12,966   Acquisition at $50 per share. 648,300
11/17/2020 Pontifax Management Co. Ltd.
26,634   Acquisition at $50 per share. 1,331,700
11/17/2020 Pontifax Management Co. Ltd.
6,000   Acquisition at $50 per share. 300,000
11/17/2020 Pontifax Management Co. Ltd.
14,400   Acquisition at $50 per share. 720,000
11/17/2020 Pontifax Management Co. Ltd.
12,966   Acquisition at $50 per share. 648,300
11/17/2020 Pontifax Management Co. Ltd.
26,634   Acquisition at $50 per share. 1,331,700
04/13/2020 Arkin Bio Ventures
Director
120,000   Acquisition at $16 per share. 1,920,000
04/13/2020 OrbiMed Advisors LLC
Director
375,200   Acquisition at $16 per share. 6,003,200
04/13/2020 OrbiMed Advisors LLC
Director
375,200   Acquisition at $16 per share. 6,003,200
04/13/2020 Jasbir S. Seehra
Chief Executive Officer; Director
20,000   Acquisition at $16 per share. 320,000
04/13/2020 Arkin Bio Ventures
Director
167,537   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Arkin Bio Ventures
Director
343,270   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Arkin Bio Ventures
Director
1,382,295   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 OrbiMed Advisors LLC
Director
148,922   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 OrbiMed Advisors LLC
Director
744,612   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 OrbiMed Advisors LLC
Director
148,922   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 OrbiMed Advisors LLC
Director
744,612   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Partners Innovation Management Co. LLC
Director
44,676   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Partners Innovation Management Co. LLC
Director
67,015   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Partners Innovation Management Co. LLC
Director
137,308   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Partners Innovation Management Co. LLC
Director
205,962   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Partners Innovation Management Co. LLC
Director
184,305   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Partners Innovation Management Co. LLC
Director
276,459   Derivative/Non-derivative trans. at $0 per share. 0
04/13/2020 Jasbir S. Seehra
Chief Executive Officer; Director
11,169   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/kros

MarketWatch News on KROS

  1. Keros Therapeutics sets IPO terms to raise up to $80 mln

    5:25 a.m. April 1, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/kros

Other News on KROS

  1. Keros Therapeutics prices equity offering at $50

    5:19 a.m. Nov. 13, 2020

    - Seeking Alpha

  2. 10-Q: KEROS THERAPEUTICS, INC.

    6:23 a.m. Aug. 13, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-Q: KEROS THERAPEUTICS, INC.

    6:18 a.m. May 22, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  4. Weekly CEO Buys Highlight

    7:40 a.m. April 20, 2020

    - GuruFocus.com

  5. IPO Update: Keros Therapeutics Proposes IPO Terms

    9:55 a.m. April 2, 2020

    - Seeking Alpha

  6. Keros Therapeutics Starts U.S. IPO Effort Amid Market Turmoil

    12:20 p.m. March 17, 2020

    - Seeking Alpha

  7. Keros Therapeutics on deck for IPO

    9:07 p.m. March 16, 2020

    - Seeking Alpha

At a Glance

Keros Therapeutics, Inc.

99 Hayden Avenue

Suite 120, Building E

Lexington, Massachusetts 02421

Phone

1 6173146297

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$10.00M

Net Income

$-12.34M

Employees

23.00

/news/pressrelease/company/us/kros

Press Releases on KROS

  1. Keros Therapeutics Set to Join Russell 2000(R) Index

    6:01 a.m. June 26, 2020

    - GlobeNewswire

  2. Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer

    7:00 a.m. May 27, 2020

    - BusinessWire - BZX

  3. Loading more headlines...
Link to MarketWatch's Slice.